Research has identified improved biomarkers of acute kidney injury (AKI). Cystatin C (CysC) is a better glomerular filtration rate marker than serum creatinine (SCr) and may improve AKI definition. 
cause of a lack of clinical trials. This is in part because the main AKI diagnostic test, serum creatinine (SCr), is suboptimal, rising late in the course of the disease and delaying treatment evaluation and application within the narrow AKI therapeutic window. 3, 4 Research on new biomarkers for early AKI diagnosis has aimed to achieve more timely AKI treatment for use in clinical care and clinical trials. [5] [6] [7] Nevertheless, the current reference standard for comparing new kidney injury biomarkers remains SCr rise, applied in AKI definitions. 4, 8, 9 In steady state, SCr is not a precise marker of glomerular filtration rate (GFR). 10, 11 Therefore, acute SCr change (which happens with AKI) could exaggerate this imprecision and may not accurately reflect corresponding acute GFR change. A suboptimal AKI reference standard (eg, SCr) thereby also contributes to lower novel biomarker diagnostic performance. Cystatin C (CysC) is a more accurate GFR estimate than SCr and is more diagnostic of chronic kidney disease. [12] [13] [14] Unlike
SCr, CysC concentrations are unaffected by muscle mass or sex, although some medications or conditions may independently influence CysC concentrations (eg, corticosteroids and thyroid disease). 15, 16 In AKI and non-AKI settings, CysC has been found to be associated with increased mortality or cardiovascular events, [17] [18] [19] [20] and CysC may be a more sensitive marker of contrast-induced AKI in adults. [21] [22] [23] Because CysC is a better marker of GFR, it is reasonable to surmise that CysC may better detect acute GFR changes with AKI. Several studies 21, 24, 25 have used acute CysC change to define AKI using a definition similar to the SCr-defined AKI definition. However, the CysC change for AKI definition has not been extensively validated in large studies to our knowledge. Because there is no gold standard AKI test for comparison, we evaluated CysC rise for defining AKI by studying CysCdefined AKI associations with renal injury biomarkers and clinical outcomes. We hypothesized that CysC rise is superior to SCr rise for defining AKI and would thus be more strongly associated with new AKI biomarkers and clinical outcomes.
Methods

Design and Participants
This analysis used pediatric data from the Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) study, 1 
Study Procedures
Patients were recruited during preoperative evaluations, within 1 month of surgery. Blood and urine samples were collected before surgery or with anesthesia induction. After surgery, blood and urine were collected within 6 hours of intensive care unit (ICU) arrival (referred to as first postoperative or 0-6 hours after surgery) and then daily for up to 5 days. Urine was collected fresh from the bladder catheter urinometer if present using cotton balls in patients wearing diapers or by clean catch in older children without a catheter. Biospecimens were centrifuged (3000g for 10 minutes), and urine supernatant and plasma were aliquoted and stored at −80°C until analyte measurement.
Data Collection
Variables collected included age, sex, race, RACHS-1 category, 26 cardiopulmonary bypass time, and preoperative medications (including angiotensin-converting enzyme inhibitors and diuretics). The RACHS-1 contains 6 categories differentiating surgical mortality risk based on procedure. Height was recorded to calculate preoperative SCr-estimated GFR (eGFR).
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Preoperative GFR was classified as normal or abnormal based on normative values for age.
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AKI Outcome Definitions
We studied SCr-defined AKI (hereafter SCr-AKI) and 
Clinical Outcomes
We evaluated length of ICU and hospital stay (LOS) and length of mechanical ventilation (LOV). There were fewer than 5 deaths, so we did not evaluate mortality as an outcome.
Analyte Measurements
Preoperative and postoperative SCr was measured at each institution's laboratory (by either modified Jaffe or enzymatic assay) and were isotope dilution mass spectrometry traceable. In-hospital death 0 2 (2.7) 0 2 (3.9)
a,e
Hospital stay 4 (3-6) 6 (4-10) 5 (6-7) 8 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) a,e
Mechanical ventilation
Abbreviations: CysC, cystatin C; CysC-AKI, CysC-defined AKI; GFR, glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range; SCr, serum creatinine; SCr-AKI, SCr-defined AKI. a Statistically significant difference across the 4 groups (P < .05, analysis of variance). b Statistically significant difference between SCr-AKI only group vs AKI by SCr and CysC group (P < .005, correction for multiple comparisons). c Defined as less than 90 mL/min/1.73 m 2 if at least 2 years old, less than 76 if 1.5 to younger than 2 years, less than 74 if 1 to younger than 1.5 years, less than 65 if 8 months to younger than 1 year, and less than 58 if 3 to younger than 8 months.
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d It was not possible to categorize this in 2 individuals (one in column 1 and another in column 2). Therefore, the group frequencies do not add up to column totals. e Longer in AKI by SCr and CysC group vs SCr-AKI only group (P = .05).
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The CysC was measured by nephelometry (BN-II; Siemens) at the Cincinnati Children's Hospital Medical Center Biomarker Laboratory, for which the coefficient of variation was 1.1%. Urine biomarkers were measured as previously described 36,37 at the Cincinnati Children's Hospital Medical Center Biomarker Laboratory (reported as concentration per milliliter and per urine creatinine). Briefly, urine neutrophil gelatinase-associated lipocalin (NGAL) and interleukin 18 (IL-18) were measured using an assay (ARCHITECT; Abbott Diagnostics) with coefficients of variation of 5% and 8%, respectively. 36 Kidney injury molecule 1 (KIM-1) and liver fatty acid-binding protein (L-FABP) were measured in multiplex format (Sekisui Diagnostics LLC) based on capture antibodies bound to 96-well plates (Multi-Assay; MesoScale Discovery), biotinylated antibodies detection, and electrochemical signal detection of streptavidin (Sulfo-Tag; MesoScale Discovery) using an imaging system (Sector Imager 2400; MesoScale Discovery). 37 The intraassay coefficient of variation is 10% or less for both KIM-1 and L-FABP assays. Individuals performing assays were blinded to clinical data.
Statistical Analysis
Percentage agreement and κ statistic were calculated to evaluate agreement between CysC-AKI and SCr-AKI definitions (presence or absence of AKI and classification across AKI severity stages). Continuous variable comparisons across groups were performed using orthogonal contrasts in analysis of variance, and categorical variables were compared using χ 2 
Results
Patients and Comparison of AKI Definitions
In total, 311 children were recruited. One patient was excluded from analysis because of missing preoperative height, and 23 patients were excluded for missing preoperative CysC, resulting in an analysis cohort of 287 children. As summarized in Table 1 , patients who had AKI defined by both SCr and CysC had an overall worse risk profile for AKI vs patients who only had AKI defined by SCr, including lower preoperative GFR and longer cardiopulmonary bypass time and aortic cross-clamp time. Patients with AKI by both SCr and CysC also had the longest LOS and LOV of all AKI definition methods and tended to have a more severe SCr-AKI severity pattern (higher stages) than patients with only SCr-AKI. No patients received preoperative corticosteroids or nonsteroidal anti-inflammatory drugs. Five patients received postoperative dialysis. As summarized in Table 2 and Table 3 The Figure shows that the highest concentrations of NGAL, IL-18, and L-FABP were found in patients with AKI by both SCr and CysC definitions, while KIM-1 was highest in patients with AKI by CysC only. Biomarkers per milliliter concentrations are shown. As summarized in Table 4 , IL-18 and KIM-1 were more strongly associated with CysC-AKI than with SCr-AKI. For example, the fifth quintile IL-18 group had an OR of 16.19 (95% CI, 3.55-73.93) vs the first quintile for CysC-AKI compared with an OR of 6.60 (95% CI, 2.76-15.76) vs the first quintile for SCr-AKI. The IL-18 was diagnostic for CysC-AKI with an area under the receiver operating characteristic curve of 0.74 vs 0.66 for SCr-AKI. Similar comparative areas under the receiver operating characteristic curve were found for urine KIM-1 but with lower magnitude. For NGAL and L-FABP, magnitudes of association between biomarkers and AKI were similar, regardless of AKI definition. There was no appreciable difference in AKI vs non-AKI biomarker concentrations for biomarkers sampled within 2 vs 2 to 6 hours after surgery.
Comparison of Clinical Outcome Associations Between AKI Definitions
Overall associations between SCr-AKI and CysC-AKI and the clinical outcomes were similar ( Table 5) . For both AKI definitions, LOS and LOV were longer in patients with AKI after adjustment for covariates. The univariate association of longer LOS and LOV in patients with AKI by both SCr and CysC (vs SCr-AKI only) in Table 1 remained statistically significant (P < .001 for all) after covariate adjustments.
Discussion
The use of CysC first emerged in nephrology research as a more accurate alternative to SCr for estimating GFR because of its de- sirable properties, including constant production, lack of association with muscle mass, and absence of renal tubular secretion. 15, 16 Several studies 12, 13, 29 have shown that, especially in children, CysC-based equations are more accurate for estimating GFR and more sensitive in detecting low GFR. Similar to the study of urine renal tubular injury biomarkers, CysC in the AKI literature has mostly been examined as an early biomarker of AKI, being shown to rise before SCr does and to predict later clinical evidence of AKI as defined by SCr. [39] [40] [41] [42] It has been purported that CysC concentration may be less affected than SCr concentration hort that immediate postoperative CysC concentration predicted the development of mild and more severe (stage 2) postoperative AKI. 34 However, CysC remains a marker of GFR and not of direct renal tubular injury. We hypothesized that, if CysC is a better marker of steady-state GFR than SCr is, it may also be a more accurate marker of GFR changes with AKI and therefore a superior way to define AKI in clinical trials, biomarker validation studies, and AKI outcome studies. We found in this study that AKI defined by acute CysC rise was more strongly associated than SCr-AKI with 2 AKI urine biomarkers of kidney injury (KIM-1 and IL-18). This is important to understand because several studies 19,21,24,25 have used CysC to define AKI. The implication is that studies using CysC change to define AKI would have different conclusions about the diagnostic ability of KIM-1 and IL-18. Association of CysC-AKI with urine NGAL was not stronger than that of SCr-AKI with urine NGAL. It is possible that urine NGAL is sensitive to AKI seen with intravascular volume depletion, which is commonly associated with acute SCr rise after surgery. Biomarker concentrations were highest in patients with both SCr-AKI and CysC-AKI. This suggests that information from both SCr and CysC change may be useful in future studies or in clinical care in which specificity of AKI diagnosis is most desirable (eg, a new drug trial, determination of preoperative risk, or decision to stop treatment with a nephrotoxic antibiotic). This should be evaluated in prospective studies with adequate sample size to evaluate AKI by both SCr and CysC as an outcome. Several North American and European centers have also begun using CysC for renal evaluation in clinical care. Therefore, it is important to understand implications of acute CysC rise in the common clinical setting of AKI in hospitalized patients. Although agreement in the presence of any AKI was only moderate between SCr-AKI and CysC-AKI, agreement between identifying stage 2 CysC-AKI and SCr-AKI was very high. This may suggest that CysC rise may be more specific for denoting the presence of true and more severe acute renal tubular injury. We also found that time to first diagnosis of CysC-AKI occurred later than time to first diagnosis of SCr-AKI (mean, 2 days vs 1 day). This may lead to the conclusion that CysC-AKI occurs later and thus that CysC is not an early AKI biomarker. However, many patients who developed SCr-AKI had stage 1 SCr-AKI but no CysC-AKI. It is possible that patients classified as having SCr-AKI immediately after surgery did not have actual renal tubular injury but simply had immediate postoperative SCr rise due to creatinine production or secretion or metabolism. This is supported by the stronger association of CysC-AKI with some of our studied renal injury biomarkers. Therefore, simply because on average CysC-AKI was detected later than SCr-AKI does not necessarily mean that it is a later AKI biomarker. Rather, our findings suggest that CysC-AKI is likely a more specific AKI biomarker. Moreover, the focus of this work was to determine if CysC is more useful for defining AKI (eg, to validate early AKI urine biomarkers) and not to evaluate CysC for early AKI diagnosis. In the clinical setting, if CysC is more specific for true AKI (ie, renal tubular injury), then CysC might be helpful to distinguish patients who are at higher risk for complications such as fluid overload and drug nephrotoxicity and who may require more intensive renal monitoring. Patients with both SCr-AKI and CysC-AKI had longer LOS and LOV, again supporting that the inclusion of CysC in determining if AKI is present increases association of AKI with outcomes. However, we did not find that CysC-AKI by itself was more strongly associated with LOS or LOV than SCr-AKI was. Therefore, as has been shown in the literature deriving GFR equations, 11, 13 in which the most accurate way to estimate GFR is by combining SCr and CysC data, the same may be true in AKI. Using both biomarkers increases the chance of identifying patients who have significant AKI. Future larger studies should evaluate whether a combined SCr and CysC AKI definition is most strongly associated with clinical outcomes, including mortality. This study had limitations. The sample size precluded us from performing subgroup analyses to evaluate associations for more severe AKI development (dialysis) and mortality outcomes. Also, we did not collect the required data to incorporate the urine output criteria for defining AKI and were unable to explore if SCr-AKI vs CysC-AKI definitions are associated with different urine output indexes. Studies 44, 45 have shown that, by correcting for SCr dilution using fluid balance measures, the diagnosis of AKI using SCr might be more specific, but we were not able to evaluate this. Our findings may not be applicable to nonpediatric cardiac surgery populations. Centers that do not have the availability of CysC measurement or that do not routinely measure CysC would not be able to evaluate CysC in clinical care without having routine preoperative CysC measurement available. We used new AKI biomarkers to evaluate the validity of CysC to define AKI, which assumes that these biomarkers have been validated for AKI diagnosis. The 4 studied biomarkers have not been extensively validated in other patient populations. However, we selected biomarkers that we know from our group's prior work are diagnostic of SCr-AKI in this specific cohort. 37,38 Moreover, in our group's previous research, 46 only urine IL-18 and KIM-1 
